A Phase I, Open-Label, Non-Randomised Study of the Absorption, Distribution, Metabolism, and Excretion of Adavosertib After a Single Oral Dose of [14C]Adavosertib to Patients With Advanced Solid Tumours
Overview
- Phase
- Phase 1
- Intervention
- [14C]Adavosertib
- Conditions
- Advanced Solid Tumors
- Sponsor
- AstraZeneca
- Enrollment
- 2
- Locations
- 1
- Primary Endpoint
- Half-life associated with terminal slope (λz) of a semi-logarithmic concentration-time curve (t½λz)
- Status
- Terminated
- Last Updated
- 3 years ago
Overview
Brief Summary
This is a non-randomised study in patients with advanced solid malignancies
Detailed Description
The aim is to recruit approximately 8 patients with a minimum number of 4 pharmacokinetics (PK) evaluable patients. Each patient will be admitted to the study site pre-dose on Day -1 and will remain at the study site until at least Day 8. Patients will receive a single administration of \[14C\]adavosertib as an oral solution on Day 1. During this study, whole blood, plasma, urine, faeces, and vomit samples (if presented) will be collected at various time points to characterise the absorption, distribution, metabolism, excretion and PK of adavosertib. The duration of the residential period will be evaluated following treatment of the first patient and may be adjusted to ensure recovery of at least 90% of the total radioactivity following the dose of \[14C\]adavosertib and/or until less than 1% of dose is recovered in urine and/or faeces within a 24-hour period.
Investigators
Eligibility Criteria
Inclusion Criteria
- •Patient must be ≥ 18 years of age.
- •Histologically or cytologically documented, locally advanced or metastatic solid tumour, excluding lymphoma, for which standard therapy does not exist or has proven ineffective or intolerable.
- •Eastern Cooperative Oncology Group performance status score of 0 to
- •Life expectancy ≥ 12 weeks.
- •Patients must have normal organ and marrow function at baseline, within 7 days prior to study drug administration.
- •Able and willing to stay in hospital for approximately 9 days (first patient; to be evaluated and possibly adjusted for subsequent patients) for the collection of samples following a single oral dose of \[14C\]-adavosertib.
- •Body weight within 50-100 kg and BMI within the range 18-30 kg/m\^2 (inclusive).
- •Regular bowel movements (i.e., on average production of at least 1 faeces per day).
- •Males and females of childbearing potential who agree to use contraceptive measures consistent with local regulations for clinical studies.
Exclusion Criteria
- •Persistent toxicities (Common Terminology Criteria for Adverse Events \[CTCAE\] Grade \> 2) caused by previous anticancer therapy, excluding alopecia and CTCAE Grade 2 peripheral neuropathy.
- •Refractory nausea and vomiting, chronic gastrointestinal disease, inability to swallow the formulated product, or previous significant bowel resection that would preclude adequate absorption, distribution, metabolism, or excretion of 14C-adavosertib oral solution.
- •Patients who have participated in another absorption, distribution, metabolism and excretion study within 1 year prior to screening.
- •Any significant cardiac diseases currently or within the last 6 months such as:
- •unstable angina pectoris
- •acute myocardial infarction, congestive heart failure
- •conduction abnormality not controlled with pacemaker or medication
- •significant ventricular or supraventricular arrhythmias
- •Any of the following: History or current evidence of congenital long QT syndrome; concomitant medications known to prolong QT interval or history of medication-related QT prolongation.
- •Known to have tested positive for human immunodeficiency virus or active tuberculosis infection.
Arms & Interventions
[14C]Adavosertib
Patients will receive a single administration of \[14C\]adavosertib as an oral solution on Day 1.
Intervention: [14C]Adavosertib
Outcomes
Primary Outcomes
Half-life associated with terminal slope (λz) of a semi-logarithmic concentration-time curve (t½λz)
Time Frame: From pre-dose to 168 hours post-dose
Assessment of t½λz of adavosertib and total radioactivity following a single oral dose of \[14C\]adavosertib.
Amount and cumulative amount excreted and expressed as the percentage of the administered dose into the urine and faeces from time t1 to time t2
Time Frame: Urine and fecal samples collected from pre-dose to 168 hours post-dose
Assessment of the mass balance of total radioactivity, including the routes and rates of elimination following a single oral dose \[14C\]adavosertib.
Maximum observed plasma concentration (Cmax)
Time Frame: From pre-dose to 168 hours post-dose
Assessment of Cmax of adavosertib and total radioactivity following a single oral dose of \[14C\]adavosertib.
Area under the plasma concentration-time curve from zero to time of last quantifiable concentration (AUClast)
Time Frame: From pre-dose to 168 hours post-dose
Assessment of AUClast of adavosertib and total radioactivity following a single oral dose of \[14C\]adavosertib.
Time to reach peak or maximum observed concentration following drug administration (tmax)
Time Frame: From pre-dose to 168 hours post-dose
Assessment of tmax of adavosertib and total radioactivity following a single oral dose of \[14C\]adavosertib.
Terminal elimination rate constant (λz)
Time Frame: From pre-dose to 168 hours post-dose
Assessment of λz of adavosertib and total radioactivity following a single oral dose of \[14C\]adavosertib.
Renal clearance of radioactivity (CLR)
Time Frame: From pre-dose to 168 hours post-dose
Assessment of renal clearance of adavosertib, including the routes and rates of elimination following a single oral dose \[14C\]adavosertib.
Area under plasma concentration-time curve from time zero to infinity (AUCinf)
Time Frame: From pre-dose to 168 hours post-dose
Assessment of AUCinf of adavosertib and total radioactivity following a single oral dose of \[14C\]adavosertib.
Apparent total body clearance of drug from plasma after extravascular administration (CL/F)
Time Frame: From pre-dose to 168 hours post-dose
Assessment of CL/F of adavosertib and total radioactivity following a single oral dose of \[14C\]adavosertib.
Mean Residence Time of the unchanged drug in the systemic circulation (MRTinf)
Time Frame: From pre-dose to 168 hours post-dose
Assessment of MRTinf of adavosertib and total radioactivity following a single oral dose of \[14C\]adavosertib.
Volume of distribution (apparent) at steady state following extravascular administration (Vss/F)
Time Frame: From pre-dose to 168 hours post-dose
Assessment of Vss/F of adavosertib and total radioactivity following a single oral dose of \[14C\]adavosertib.
Apparent volume of distribution during the terminal phase after extravascular administration (Vz/F)
Time Frame: From pre-dose to 168 hours post-dose
Assessment of Vz/F of adavosertib and total radioactivity following a single oral dose of \[14C\]adavosertib.
Ratio of AUCinf of plasma adavosertib relative to AUCinf of plasma total radioactivity [AUCinf Plasma:Total Plasma Ratio]
Time Frame: From pre-dose to 168 hours post-dose
Assessment of AUCinf plasma adavosertib:Total plasma radioactivity ratio following a single oral dose of \[14C\]adavosertib.
Ratio of AUCinf of whole blood total radioactivity to AUCinf of plasma total radioactivity [AUCinf Blood:Plasma Ratio]
Time Frame: From pre-dose to 168 hours post-dose
Assessment of AUCinf Blood:Plasma Ratio total radioactivity following a single oral dose of \[14C\]adavosertib.
Amount, cumulative amount, and cumulative percentage of unchanged adavosertib excreted into urine from time t1 to time t2
Time Frame: Urine collected from pre-dose to 168 hours post-dose
Assessment of unchanged adavosertib following a single oral dose of \[14C\]adavosertib.
Renal clearance of adavosertib from plasma (CLR)
Time Frame: From pre-dose to 168 hours post-dose
Assessment of CLR of adavosertib and total radioactivity following a single oral dose of \[14C\]adavosertib.
Secondary Outcomes
- Number of patients with adverse events (AE) and serious AEs (SAE)(From screening (Day -28 to Day -1) until end of study (within 30 [±7] days of adavosertib dose))